These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34462327)

  • 1. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
    Robbins Y; Friedman J; Clavijo PE; Sievers C; Bai K; Donahue RN; Schlom J; Sinkoe A; Hinrichs CS; Allen C; Abdul Sater H; Gulley JL; Norberg S
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
    Allen CT; Lee S; Norberg SM; Kovalovsky D; Ye H; Clavijo PE; Hu-Lieskovan S; Schlegel R; Schlom J; Strauss J; Gulley JL; Trepel J; Hinrichs CS
    J Immunother Cancer; 2019 May; 7(1):119. PubMed ID: 31053174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.
    Tschernia NP; Gulley JL
    BioDrugs; 2022 Mar; 36(2):153-180. PubMed ID: 35353346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
    Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
    Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
    Gameiro SR; Strauss J; Gulley JL; Schlom J
    Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
    Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
    Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
    Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
    Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
    Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
    Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
    Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.
    Redman JM; Friedman J; Robbins Y; Sievers C; Yang X; Lassoued W; Sinkoe A; Papanicolau-Sengos A; Lee CC; Marte JL; Turkbey E; Mydlarz W; Joshi A; London NR; Pierce M; Taylor R; Hong S; Nguyen A; Soon-Shiong P; Schlom J; Gulley JL; Allen CT
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35727629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis.
    Lam B; Miller J; Kung YJ; Wu TC; Hung CF; Roden RBS; Best SR
    Laryngoscope; 2024 Jun; 134(6):2819-2825. PubMed ID: 38193541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restricted Recruitment of NK Cells with Impaired Function Is Caused by HPV-Driven Immunosuppressive Microenvironment of Papillomas in Aggressive Juvenile-Onset Recurrent Respiratory Papillomatosis Patients.
    Wang W; Xi Y; Li S; Liu X; Wang G; Wang H; Pei M; Zhang J; Gui J; Ni X
    J Virol; 2022 Oct; 96(19):e0094622. PubMed ID: 36154611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabelling and preclinical characterization of
    Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis.
    Creelan BC; Ahmad MU; Kaszuba FJ; Khalil FK; Welsh AW; Ozdemirli M; Grant NN; Subramaniam DS
    Oncologist; 2019 Jun; 24(6):829-835. PubMed ID: 30842242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa.
    Tsai YT; Strauss J; Toney NJ; Jochems C; Venzon DJ; Gulley JL; Schlom J; Donahue RN
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35418484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.